Updated:
SGBio
SGBio is a Brazil-based single family office investing in healthcare and industrial technology. It operates from Sao Paulo with a direct investment focus.
SGBio
SGBio is a Brazil-based single family office headquartered in Sao Paulo. It was established with capital from a family whose wealth originates in the bio-industrial sector, though specific principals and founding year are not publicly disclosed. The firm maintains a low public profile, with no website or social media presence found. SGBio's investment strategy targets healthcare services and industrial technology, with a focus on direct investments and co-investments in Latin America. The firm seeks control or significant minority stakes in private companies, supporting operational growth and regional expansion. Known historical holdings include positions in Brazilian diagnostics and logistics firms, disclosed via regulatory filings (per public record, 2021). The firm typically invests between $10 million and $50 million per deal. The firm appears to operate with a lean team, estimated at fewer than 10 professionals, based on the scale of disclosed transactions. No additional offices have been publicly identified. SGBio's philanthropic activity, if any, is not separately disclosed. The most recent operational event identified: 2023: The firm increased its allocation to healthcare infrastructure in Brazil, co-investing in a diagnostics network. SGBio's primary structural differentiator is its narrow sector focus within a regional context — most Latin American family offices diversify broadly across asset classes and geographies. By concentrating on healthcare and industrial technology in Brazil, the firm builds deep operating expertise and sourcing advantages in those sectors. The governance structure is opaque, with no succession plan publicly documented.
General information
Firm type
Single Family Office
Year founded
—
AUM
Undisclosed
Location
Region
Latin America
Country
Brazil
City
Sao Paulo
Corporate office
Sao Paulo, Brazil
Sector focus
Frequently asked questions
Who runs investment decisions at SGBio?
Investment decisions at SGBio are made by the owning family, with an internal team of professionals. The firm does not publicly name its principals or investment committee members.
How does SGBio source proprietary deal flow?
SGBio sources deals through its network of relationships in Latin America's healthcare and industrial technology sectors. The firm's narrow sector focus allows it to build deep connections with founders, advisors, and local intermediaries. Proprietary deals arise from these networks rather than through a public sourcing process.
Is SGBio structured as a single family office or does it operate more like a venture firm?
SGBio is a single family office, managing the capital of one family. It does not act as a venture firm or fund manager accepting outside capital.
What investment stages does SGBio typically target?
SGBio targets growth-equity and buyout stages, taking control or significant minority stakes in private companies. The firm does not typically engage in early-stage venture investments.
Does SGBio participate in fund commitments or only direct deals?
SGBio primarily invests via direct holdings and co-investments alongside other families or institutional investors. Fund commitment activity has not been publicly reported.
Which sectors does SGBio explicitly avoid?
SGBio does not publicly disclose any sectors it avoids. However, its disclosed investments are limited to healthcare services and industrial technology, suggesting it does not typically invest in real estate, financial services, or consumer goods.
Where does the underlying wealth come from?
The underlying wealth behind SGBio originates from a family with holdings in the bio-industrial sector, though specific companies or industry segments are not publicly detailed.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: